Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

ABSTRACT:

Background

Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known.

Objective

To identify genomic and histologic features associated with treatment resistance at baseline.

Design, setting, and participants

Targeted biopsies were obtained from 37 men with intermediate- to high-risk prostate cancer before receiving 6 mo of ADT plus enzalutamide. Biopsy tissues were used for whole-exome sequencing and immunohistochemistry (IHC).

Outcome measurements and statistical

SUBMITTER: Wilkinson S 

PROVIDER: S-EPMC8473585 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature